MapLight Therapeutics, Inc. Common Stock (MPLT) Live Share Price, Invest From India

MapLight Therapeutics, Inc. Common Stock Stock Performance

as on May 14, 2026 at 2:15 pm IST

Day's Low
Day's High
$29.43
Day's Price Range
$31.34
$30.67
4.04%
Downside
2.18%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$30.67
100.00%
Downside
-100.00%
Upside

MapLight Therapeutics, Inc. Common Stock share price movements today

Previous Close: $30.30
Open: $30.13
Volume: 223.2K
Day's Low - High: $29.43 - $31.34

MapLight Therapeutics, Inc. Common Stock Historical Returns

1 Month Return: + 12.14 %
3 Month Return: + 75.96 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

MapLight Therapeutics, Inc. Common Stock Stock Fundamentals & Key Indicators

Check MapLight Therapeutics, Inc. Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-4.545

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-56.19%

MapLight Therapeutics, Inc. Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MapLight Therapeutics, Inc. Common Stock with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
MapLight Therapeutics, Inc. Common Stock	NA	$1.3B	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$38.0B	115.2%	71.39	12.55%
BeiGene, Ltd.	NA	$32.7B	NA	71.44	8.94%
Vertex Pharmaceuticals Inc	BUY	$110.4B	106.5%	25.84	35.51%
Regeneron Pharmaceuticals Inc	BUY	$74.7B	40.03%	17.39	29.65%

Indian Investors' Interest in MapLight Therapeutics, Inc. Common Stock Stock

Search interest for MapLight Therapeutics, Inc. Common Stock Stock has increased by 150% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 14, 2026 to May 14, 2026

Change:150% versus previous 30 day period

MapLight Therapeutics, Inc. Common Stock Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2024	Dec 2024	Sep 2025	Dec 2025
Total Revenue	-	-	-	-
Gross Profit	-	-	0	0
Operating Income	-20	-22	-31	-83
EBITDA	-20	-22	-31	-83
Interest Expense	-	-	-	-
Depreciation	0	0	0	0
Income Before Tax	-19	-21	-29	-79
Income Tax Expense	-	-	-	-
Net Income	-19	-21	-29	-79
Net Profit Margin	0.00%	0.00%	0.00%	0.00%

MapLight Therapeutics, Inc. Common Stock Annual Profit & Loss

All numbers in Millions USD

	Dec 2025
Total Revenue	-
Gross Profit	0
Operating Income	-169
EBITDA	-168
Interest Expense	-
Depreciation	0
Income Before Tax	-161
Income Tax Expense	-
Net Income	-161
Net Profit Margin	0.00%

MapLight Therapeutics, Inc. Common Stock Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-18	-18	-19	-21	-22	-29	-29	-79
Operating Cash Flow	-19	-17	-19	-21	-25	-33	-31	-46
Investing Cash Flow	0	-121	8	32	37	17	-135	-242
Financing Cash Flow	119	-1	0	0	0	0	198	271
Change in Cash	179	-179	-11	10	50	-16	30	-17

MapLight Therapeutics, Inc. Common Stock Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	-55	-77	-161
Operating Cash Flow	-52	-78	-138
Investing Cash Flow	0	-80	-323
Financing Cash Flow	104	118	469
Change in Cash	52	-41	8

Insights on MapLight Therapeutics, Inc. Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, MPLT stock has moved up by 76.0%

About MapLight Therapeutics, Inc. Common Stock

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Organisation	MapLight Therapeutics, Inc. Common Stock
Headquarters	800 Chesapeake Drive, Redwood City, CA, United States, 94063
Industry	Biotechnology
CEO	Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of MapLight Therapeutics, Inc. Common Stock

Name	Title
Dr. Robert C. Malenka M.D., Ph.D.	Co-Founder, Member of Scientific Advisory Board & Director
Mr. Vishwas Setia	Chief Financial Officer
Dr. Karoly Nikolich Ph.D.	Founder
Mr. Kristopher L. Hanson J.D.	General Counsel & Secretary
Dr. Anatol Kreitzer Ph.D.	Chief Discovery Officer
Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.	Founder, President, CEO & Director
Dr. Erin Pennock Foff M.D., Ph.D.	Chief Medical Officer
Dr. Karl Deisseroth M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board
Dr. James Woodruff Lillie Ph.D.	Chief Scientific Officer

FAQs

What is MapLight Therapeutics, Inc. Common Stock share price today?

MapLight Therapeutics, Inc. Common Stock share price today is $30.67 as on May 14, 2026 at 8:45 am IST at the close of the market. MapLight Therapeutics, Inc. Common Stock share today touched a day high of $31.34 and a low of $29.43.

What is the 52 week high and 52 week low for MapLight Therapeutics, Inc. Common Stock share?

MapLight Therapeutics, Inc. Common Stock share touched a 52 week high of $ on January 1, 1970 and a 52 week low of $ on January 1, 1970. MapLight Therapeutics, Inc. Common Stock stock price today i.e. May 14, 2026 at 8:45 am IST is closed at $30.67,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is MapLight Therapeutics, Inc. Common Stock's market capitalisation today?

MapLight Therapeutics, Inc. Common Stock market capitalisation is $0.00T as on May 14, 2026 at 8:45 am IST.

How to invest in MapLight Therapeutics, Inc. Common Stock Stock (MPLT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for MapLight Therapeutics, Inc. Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in MapLight Therapeutics, Inc. Common Stock Shares that will get you 0.0489 shares as per MapLight Therapeutics, Inc. Common Stock share price of $30.67 per share as on May 14, 2026 at 8:45 am IST.

What is the minimum amount required to buy MapLight Therapeutics, Inc. Common Stock Stock (MPLT) from India?

Indian investors can start investing in MapLight Therapeutics, Inc. Common Stock (MPLT) shares with as little as ₹95.705 or $1 (as of May 14, 2026 at 2:47 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in MapLight Therapeutics, Inc. Common Stock stock (as per the Rupee-Dollar exchange rate as on May 14, 2026 at 2:47 pm IST). Based on MapLight Therapeutics, Inc. Common Stock share’s latest price of $30.67 as on May 14, 2026 at 8:45 am IST, you will get 0.3261 shares of MapLight Therapeutics, Inc. Common Stock. Learn more about fractional shares .